Phenotype standardization for statin-induced myotoxicity.
Publication
, Journal Article
Alfirevic, A; Neely, D; Armitage, J; Chinoy, H; Cooper, RG; Laaksonen, R; Carr, DF; Bloch, KM; Fahy, J; Hanson, A; Yue, Q-Y; Wadelius, M ...
Published in: Clin Pharmacol Ther
October 2014
Statins are widely used lipid-lowering drugs that are effective in reducing cardiovascular disease risk. Although they are generally well tolerated, they can cause muscle toxicity, which can lead to severe rhabdomyolysis. Research in this area has been hampered to some extent by the lack of standardized nomenclature and phenotypic definitions. We have used numerical and descriptive classifications and developed an algorithm to define statin-related myotoxicity phenotypes, including myalgia, myopathy, rhabdomyolysis, and necrotizing autoimmune myopathy.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
October 2014
Volume
96
Issue
4
Start / End Page
470 / 476
Location
United States
Related Subject Headings
- Time Factors
- Terminology as Topic
- Risk Factors
- Rhabdomyolysis
- Phenotype
- Pharmacology & Pharmacy
- Myositis
- Myalgia
- Muscular Diseases
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
Citation
APA
Chicago
ICMJE
MLA
NLM
Alfirevic, A., Neely, D., Armitage, J., Chinoy, H., Cooper, R. G., Laaksonen, R., … Pirmohamed, M. (2014). Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther, 96(4), 470–476. https://doi.org/10.1038/clpt.2014.121
Alfirevic, A., D. Neely, J. Armitage, H. Chinoy, R. G. Cooper, R. Laaksonen, D. F. Carr, et al. “Phenotype standardization for statin-induced myotoxicity.” Clin Pharmacol Ther 96, no. 4 (October 2014): 470–76. https://doi.org/10.1038/clpt.2014.121.
Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014 Oct;96(4):470–6.
Alfirevic, A., et al. “Phenotype standardization for statin-induced myotoxicity.” Clin Pharmacol Ther, vol. 96, no. 4, Oct. 2014, pp. 470–76. Pubmed, doi:10.1038/clpt.2014.121.
Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, Carr DF, Bloch KM, Fahy J, Hanson A, Yue Q-Y, Wadelius M, Maitland-van Der Zee AH, Voora D, Psaty BM, Palmer CNA, Pirmohamed M. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther. 2014 Oct;96(4):470–476.
Published In
Clin Pharmacol Ther
DOI
EISSN
1532-6535
Publication Date
October 2014
Volume
96
Issue
4
Start / End Page
470 / 476
Location
United States
Related Subject Headings
- Time Factors
- Terminology as Topic
- Risk Factors
- Rhabdomyolysis
- Phenotype
- Pharmacology & Pharmacy
- Myositis
- Myalgia
- Muscular Diseases
- Hydroxymethylglutaryl-CoA Reductase Inhibitors